Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies

Shirish Gadgeel,1 Alice T Shaw,2 Fabrice Barlesi,3 Lucio Crino,4 James CH Yang,5 Anne-Marie Dingemans,6 Dong-Wan Kim,7 Filippo de Marinis,8 Mathias Schulz,8 Shiyao Liu,9 Ravindra Gupta,9 Vlatka Smoljanovic,10 Sai-Hong Ignatius Ou11 1Department of Internal Medicine, Division of Hematology and Oncolog...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gadgeel S, Shaw AT, Barlesi F, Crino L, Yang JCH, Dingemans AM, Kim DW, de Marinis F, Schulz M, Liu S, Gupta R, Smoljanovic V, Ou SHI
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	alectinib non-small-cell lung cancer np28673 np28761 time to response Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/be4ff09e7ee3407b8b960a718417af5e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:be4ff09e7ee3407b8b960a718417af5e
record_format	dspace
spelling	oai:doaj.org-article:be4ff09e7ee3407b8b960a718417af5e2021-12-02T02:19:13ZTime To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies1179-2728https://doaj.org/article/be4ff09e7ee3407b8b960a718417af5e2019-11-01T00:00:00Zhttps://www.dovepress.com/time-to-response-in-patients-with-advanced-anaplastic-lymphoma-kinase--peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Shirish Gadgeel,1 Alice T Shaw,2 Fabrice Barlesi,3 Lucio Crino,4 James CH Yang,5 Anne-Marie Dingemans,6 Dong-Wan Kim,7 Filippo de Marinis,8 Mathias Schulz,8 Shiyao Liu,9 Ravindra Gupta,9 Vlatka Smoljanovic,10 Sai-Hong Ignatius Ou11 1Department of Internal Medicine, Division of Hematology and Oncology, The University of Michigan, Ann Arbor, MI 48109, USA; 2Center for Thoracic Cancers, Massachusetts General Hospital, Boston, MA, USA; 3Multidisciplinary Oncology and Therapeutic Innovations Department, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille 13005, France; 4Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl I.R.C.C.S., Meldola, FC 47014, Italy; 5National Taiwan University Hospital and National Taiwan University Cancer Centre, Taipei City, Taiwan; 6Department of Pulmonology, Maastricht University Medical Centre, Maastricht 6229 HX, The Netherlands; 7Department of Internal Medicine, Seoul National University Hospital, Jongno-Gu, Seoul 03080, South Korea; 8Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan 20146, Italy; 9Genentech Inc., South San Francisco, CA, USA; 10F. Hoffmann-La Roche Ltd., Basel CH-4070, Switzerland; 11Division of Hematology-Medical Oncology, Department of Internal Medicine, University of California, Irvine School of Medicine, Orange, CA 92617, USACorrespondence: Sai-Hong Ignatius OuUniversity of California, Irvine School of Medicine, 1001 Health Sciences Road, Irvine, Orange, CA 92617, USATel +1 714 456 8104Email siou@uci.eduIntroduction: Alectinib is a highly selective and potent ALK inhibitor, approved for the treatment of patients with metastatic ALK+ NSCLC based on results from the Phase II global NP28673 (NCT01801111) and North American NP28761 (NCT01871805) studies.Methods: This exploratory analysis of two Phase II studies of alectinib (NP28673/NP28761) investigated time to systemic response (TTR) and time to central nervous system (CNS) response (TTCR) in patients with previously treated advanced anaplastic lymphoma kinase fusion gene-positive (ALK+) non-small-cell lung cancer. Patients (n=225) received 600 mg oral alectinib twice daily and had scans every 6/8 weeks (NP28673/NP28761).Results: For NP28673 and NP28761, respectively: median follow-up was 21.3 months/17.0 months; most responders (72.6%/82.9%) responded by the first disease assessment; median TTR was 8 weeks (95% confidence interval [CI]: 8.00–8.14)/6 weeks (95% CI: 5.86–6.14); median TTCR in responders with measurable baseline CNS disease was 8 weeks (95% CI: 7.86–10.29)/6 weeks (95% CI: 5.71–not evaluable). Similar results were observed regardless of measurable/non-measurable disease.Discussion: These data suggest that alectinib achieves a rapid response in patients, both systemically and in the CNS.Keywords: alectinib, non-small-cell lung cancer, NP28673, NP28761, time to responseGadgeel SShaw ATBarlesi FCrino LYang JCHDingemans AMKim DWde Marinis FSchulz MLiu SGupta RSmoljanovic VOu SHIDove Medical Pressarticlealectinibnon-small-cell lung cancernp28673np28761time to responseNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 10, Pp 125-130 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	alectinib non-small-cell lung cancer np28673 np28761 time to response Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	alectinib non-small-cell lung cancer np28673 np28761 time to response Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Gadgeel S Shaw AT Barlesi F Crino L Yang JCH Dingemans AM Kim DW de Marinis F Schulz M Liu S Gupta R Smoljanovic V Ou SHI Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies
description	Shirish Gadgeel,1 Alice T Shaw,2 Fabrice Barlesi,3 Lucio Crino,4 James CH Yang,5 Anne-Marie Dingemans,6 Dong-Wan Kim,7 Filippo de Marinis,8 Mathias Schulz,8 Shiyao Liu,9 Ravindra Gupta,9 Vlatka Smoljanovic,10 Sai-Hong Ignatius Ou11 1Department of Internal Medicine, Division of Hematology and Oncology, The University of Michigan, Ann Arbor, MI 48109, USA; 2Center for Thoracic Cancers, Massachusetts General Hospital, Boston, MA, USA; 3Multidisciplinary Oncology and Therapeutic Innovations Department, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille 13005, France; 4Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl I.R.C.C.S., Meldola, FC 47014, Italy; 5National Taiwan University Hospital and National Taiwan University Cancer Centre, Taipei City, Taiwan; 6Department of Pulmonology, Maastricht University Medical Centre, Maastricht 6229 HX, The Netherlands; 7Department of Internal Medicine, Seoul National University Hospital, Jongno-Gu, Seoul 03080, South Korea; 8Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan 20146, Italy; 9Genentech Inc., South San Francisco, CA, USA; 10F. Hoffmann-La Roche Ltd., Basel CH-4070, Switzerland; 11Division of Hematology-Medical Oncology, Department of Internal Medicine, University of California, Irvine School of Medicine, Orange, CA 92617, USACorrespondence: Sai-Hong Ignatius OuUniversity of California, Irvine School of Medicine, 1001 Health Sciences Road, Irvine, Orange, CA 92617, USATel +1 714 456 8104Email siou@uci.eduIntroduction: Alectinib is a highly selective and potent ALK inhibitor, approved for the treatment of patients with metastatic ALK+ NSCLC based on results from the Phase II global NP28673 (NCT01801111) and North American NP28761 (NCT01871805) studies.Methods: This exploratory analysis of two Phase II studies of alectinib (NP28673/NP28761) investigated time to systemic response (TTR) and time to central nervous system (CNS) response (TTCR) in patients with previously treated advanced anaplastic lymphoma kinase fusion gene-positive (ALK+) non-small-cell lung cancer. Patients (n=225) received 600 mg oral alectinib twice daily and had scans every 6/8 weeks (NP28673/NP28761).Results: For NP28673 and NP28761, respectively: median follow-up was 21.3 months/17.0 months; most responders (72.6%/82.9%) responded by the first disease assessment; median TTR was 8 weeks (95% confidence interval [CI]: 8.00–8.14)/6 weeks (95% CI: 5.86–6.14); median TTCR in responders with measurable baseline CNS disease was 8 weeks (95% CI: 7.86–10.29)/6 weeks (95% CI: 5.71–not evaluable). Similar results were observed regardless of measurable/non-measurable disease.Discussion: These data suggest that alectinib achieves a rapid response in patients, both systemically and in the CNS.Keywords: alectinib, non-small-cell lung cancer, NP28673, NP28761, time to response
format	article
author	Gadgeel S Shaw AT Barlesi F Crino L Yang JCH Dingemans AM Kim DW de Marinis F Schulz M Liu S Gupta R Smoljanovic V Ou SHI
author_facet	Gadgeel S Shaw AT Barlesi F Crino L Yang JCH Dingemans AM Kim DW de Marinis F Schulz M Liu S Gupta R Smoljanovic V Ou SHI
author_sort	Gadgeel S
title	Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies
title_short	Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies
title_full	Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies
title_fullStr	Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies
title_full_unstemmed	Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies
title_sort	time to response in patients with advanced anaplastic lymphoma kinase (alk)-positive non-small-cell lung cancer (nsclc) receiving alectinib in the phase ii np28673 and np28761 studies
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/be4ff09e7ee3407b8b960a718417af5e
work_keys_str_mv	AT gadgeels timetoresponseinpatientswithadvancedanaplasticlymphomakinasealkpositivenonsmallcelllungcancernsclcreceivingalectinibinthephaseiinp28673andnp28761studies AT shawat timetoresponseinpatientswithadvancedanaplasticlymphomakinasealkpositivenonsmallcelllungcancernsclcreceivingalectinibinthephaseiinp28673andnp28761studies AT barlesif timetoresponseinpatientswithadvancedanaplasticlymphomakinasealkpositivenonsmallcelllungcancernsclcreceivingalectinibinthephaseiinp28673andnp28761studies AT crinol timetoresponseinpatientswithadvancedanaplasticlymphomakinasealkpositivenonsmallcelllungcancernsclcreceivingalectinibinthephaseiinp28673andnp28761studies AT yangjch timetoresponseinpatientswithadvancedanaplasticlymphomakinasealkpositivenonsmallcelllungcancernsclcreceivingalectinibinthephaseiinp28673andnp28761studies AT dingemansam timetoresponseinpatientswithadvancedanaplasticlymphomakinasealkpositivenonsmallcelllungcancernsclcreceivingalectinibinthephaseiinp28673andnp28761studies AT kimdw timetoresponseinpatientswithadvancedanaplasticlymphomakinasealkpositivenonsmallcelllungcancernsclcreceivingalectinibinthephaseiinp28673andnp28761studies AT demarinisf timetoresponseinpatientswithadvancedanaplasticlymphomakinasealkpositivenonsmallcelllungcancernsclcreceivingalectinibinthephaseiinp28673andnp28761studies AT schulzm timetoresponseinpatientswithadvancedanaplasticlymphomakinasealkpositivenonsmallcelllungcancernsclcreceivingalectinibinthephaseiinp28673andnp28761studies AT lius timetoresponseinpatientswithadvancedanaplasticlymphomakinasealkpositivenonsmallcelllungcancernsclcreceivingalectinibinthephaseiinp28673andnp28761studies AT guptar timetoresponseinpatientswithadvancedanaplasticlymphomakinasealkpositivenonsmallcelllungcancernsclcreceivingalectinibinthephaseiinp28673andnp28761studies AT smoljanovicv timetoresponseinpatientswithadvancedanaplasticlymphomakinasealkpositivenonsmallcelllungcancernsclcreceivingalectinibinthephaseiinp28673andnp28761studies AT oushi timetoresponseinpatientswithadvancedanaplasticlymphomakinasealkpositivenonsmallcelllungcancernsclcreceivingalectinibinthephaseiinp28673andnp28761studies
_version_	1718402552961171456

Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies

Ejemplares similares